The combination chemotherapy of carboplatin and TS-1 followed by the maintenance therapy of TS-1 in advanced non-small cell lung cancer. Phase 2 trial.

The combination chemotherapy of carboplatin and TS-1 followed by the maintenance therapy of TS-1 in advanced non-small cell lung cancer. Phase 2 trial. - TS-1 plus CBDCA followed by TS-1 in advanced NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025932

Enrollment

Registered

2017-01-31

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

A combination chemotherapy of TS-1 and carboplation followed by the maintenance therapy of TS-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologacally or cytologically proven NSCLC 2) Stage 3B or 4 3) Patients who can take food orally 4) Presence of measurable lesions 5) Age 70-74, PS 2 or age 75 or over, PS0-1

Exclusion criteria

Exclusion criteria: 1) Severe drug allergy 2) Uncontrolable effusion 3) Within 2 weeks after radiotherapy for lesions except primary lesion. 4) Continuous watery diarrhea 5) Active double cancer 6) EGFR mutation positive or ALK fusion gene positive non-squamous cell carcinoma 7) Severe complications

Design outcomes

Primary

Measure	Time frame
Progression free survival from the initiation of an induction chemotherapy, TS-1 plus CBDCA	—

Countries

Japan

Contacts

Public ContactYukihiro Umeda, M.D.

University of Fukui Hospital Division of Respiratory Medicine

umeda@u-fukui.ac.jp0776-61-8355

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026